New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment [PDF]
, 2016 © 2015, Sociedade Brasileira de Medicina Tropical. All rights reserved. Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization.
Chávez-Fumagalli, Miguel A. +2 more
core +1 more source
Comparison of the Activity of Free and Liposomal Amphotericin B In Vitro and in a Model of Systemic and Localized Murine Candidiasis [PDF]
, 2017 Because of the toxicity of amphotericin B-desoxycholate (AmB-d) during systemic therapy, less toxic forms of AmB, which promise to have a broader therapeutic index, are under investigation.
Pahls, Stephan, Schaffner, Andreas
core
Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya. [PDF]
, 2013 Between 2000 and 2010, Médecins Sans Frontières diagnosed and treated 4,831 patients with visceral leishmaniasis (VL) in the Pokot region straddling the border between Uganda and Kenya. A retrospective analysis of routinely collected clinical data showed
Brooker, Simon J +7 more
core +2 more sources
Antifungal activity of caspofungin in experimental infective endocarditis caused by Candida albicans
Memorias do Instituto Oswaldo CruzBACKGROUND Infective endocarditis is a disease characterised by heart valve lesions, which exhibit extracellular matrix proteins that act as a physical barrier to prevent the passage of antimicrobial agents.
Gerardo Becerra Victorio +7 more
doaj +1 more source
Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B. [PDF]
, 2018 Disfiguring skin lesions caused by several species of the Leishmania parasite characterize cutaneous leishmaniasis (CL). Successful treatment of CL with intravenous (i.v.) liposomal amphotericin B (LAmB) relies on the presence of adequate antibiotic ...
Alavijeh, Mo +7 more
core +2 more sources
Recurrent Candida albicans Ventriculitis Treated with Intraventricular Liposomal Amphotericin B
Case Reports in Infectious Diseases, 2015 Central nervous system (CNS) infection with Candida is rare but significant because of its high morbidity and mortality. When present, it is commonly seen among immunocompromised and hospitalized patients.
Demet Toprak +5 more
doaj +1 more source
Journal of Microbiology and Infectious Diseases, 2016 In this paper, we present a 69 years old diabetic patient with mucormycosis who was succesfully treated with liposomal amphotericin B (LAMB), posaconazole and deferasirox despite having no adequate surgery.
Uğur Onal +6 more
doaj +1 more source
Five-year retrospective italian multicenter study of visceral leishmaniasis treatment [PDF]
, 2013 The treatment of visceral leishmaniasis (VL) is poorly standardized in Italy in spite of the existing evidence. All consecutive patients with VL admitted at 15 Italian centers as inpatients or outpatients between January 2004 and December 2008 were ...
Almi, P. +25 more
core +1 more source
Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice [PDF]
, 2003 Objective: To study the toxicity and activity of two new amphotericin B formulations: poly(ε-caprolactone) nanospheres coated with poloxamer 188 (AmB-NP) and mixed micelles with the same surfactant (AmB-MM). Materials and methods: The toxicity of these
Appel, M. (M.) +7 more
core +1 more source
The direct costs of treating human visceral leishmaniasis in Brazil
Revista da Sociedade Brasileira de Medicina TropicalINTRODUCTION: The drugs available for visceral leishmaniasis (VL) treatment in Brazil have specific characteristics in terms of operability, effectiveness, toxicity, and cost.
Tália Santana Machado de Assis +6 more
doaj +1 more source